PainChek

PainChek CapEx/D&A

The CapEx to Depreciation Ratio of PainChek (PCK.AX) as of Nov 11, 2026 is 0.85. In the previous year, CapEx to Depreciation Ratio was 6.67 — a change of -87.26% (lower).

CapEx/D&A

0.85

YoY

-87.26%

Last updated:

CapEx to Depreciation Ratio of PainChek is 2016 0.85 . CapEx to Depreciation Ratio of PainChek was 2015 6.67 . It decreases by -87.26% lower compared to the previous year.

The PainChek CapEx/D&A history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CapEx/D&A
Date
CapEx/D&A
Jan 1, 2014
0.05 AUD
Jan 1, 2015
6.67 AUD
Jan 1, 2016
0.85 AUD
The PainChek CapEx/D&A history
YEARCapEx/D&AYoY
0.85-87.26%
6.67+13,881.67%
0.05—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PainChek Stock analysis

What does PainChek do? PainChek Ltd. develops and commercializes mobile medical device applications, focusing on pain assessment for individuals unable to communicate with carers. The PainChek Universal combines the PainChek Application with the numerical rating scale (NRS), using artificial intelligence and facial recognition to detect pain in non-verbal patients. It provides a point-of-care solution that offers objectivity and consistency in pain assessments, supporting both non-verbal and self-reporting individuals through integrated tools. Healthcare providers and care facilities purchase PainChek Universal to enhance pain management protocols for patients with communication difficulties. The PainChek Application utilizes artificial intelligence and facial recognition technology to assess pain without relying on patient self-reporting, making it suitable for those with cognitive or physical impairments. PainChek Universal integrates the NRS for patients who can self-report, ensuring a comprehensive approach to pain evaluation across varying patient capabilities. This dual functionality allows healthcare professionals to apply consistent assessment standards regardless of a patient's ability to communicate. PainChek Ltd. generates revenue through the commercialization of its mobile medical device applications, specifically targeting healthcare providers and care facilities that require standardized pain assessment tools. The company’s products are designed to address the needs of patients who cannot communicate pain, thereby filling a critical gap in healthcare services. By offering a unified solution that combines AI-driven detection with traditional rating scales, PainChek Universal meets the demands of modern healthcare environments seeking objective and reliable pain management solutions. PainChek is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PainChek stock

CapEx to Depreciation Ratio of PainChek is 0.85 in 2016.

CapEx to Depreciation Ratio of PainChek changed from 6.67 to 0.85, representing a -87.26% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of CapEx to Depreciation Ratio PainChek since 2006 – with annual values, charts, and detailed analysis.

The CapEx/D&A ratio compares investment spending to asset depreciation. Ratios above 1.0x indicate the company is growing its asset base, below 1.0x suggests underinvestment.

A 'good' varies by industry and company stage. On Eulerpool, you can compare CapEx to Depreciation Ratio's PainChek with sector peers and the industry average to assess whether it is attractive.

To evaluate CapEx to Depreciation Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for CapEx to Depreciation Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — PainChek

All Key Metrics — PainChek